The growth of new applications like facemasks is one of the three reasons for expansion of the market size of antimicrobial treatments. Before 2020 there were almost no antimicrobial facemasks, and following the outbreak of Covid-19 facemasks alone are estimated to be a $21 billion business by 2026.
The growth of new applications like facemasks is one of the three reasons for expansion of the market size of antimicrobial treatments. Before 2020 there were almost no antimicrobial facemasks, and following the outbreak of Covid-19 facemasks alone are estimated to be a $21 billion business by 2026, says Ulrika Björk, chief executive officer of Polygiene.#
The growth in the number of players offering antimicrobial technologies, and the increasing size of the share with the brands collections are the other two reasons for expansion of market size of antimicrobial treatments, says Ulrika Björk, CEO of Swedish Stays Fresh technology provider Polygiene, in an interview in the August edition of Fibre2Fashion.
The growth of new applications like facemasks is one of the three reasons for expansion of the market size of antimicrobial treatments. Before 2020 there were almost no antimicrobial facemasks, and following the outbreak of Covid-19 facemasks alone are estimated to be a $21 billion business by 2026, says Ulrika Björk, chief executive officer of Polygiene.#
"Our knowledge and experience in the antimicrobial business is the foundation of our company. We exist because of SARS, when the demand for antimicrobials increased. When the novel Coronavirus started to spread, we could very fast adjust and pick up old test data and formulations," adds Björk
in the interview.
The growth of new applications like facemasks is one of the three reasons for expansion of the market size of antimicrobial treatments. Before 2020 there were almost no antimicrobial facemasks, and following the outbreak of Covid-19 facemasks alone are estimated to be a $21 billion business by 2026, says Ulrika Björk, chief executive officer of Polygiene.#
The growth of new applications like facemasks is one of the three reasons for expansion of the market size of antimicrobial treatments. Before 2020 there were almost no antimicrobial facemasks, and following the outbreak of Covid-19 facemasks alone are estimated to be a $21 billion business by 2026, says Ulrika Björk, chief executive officer of Polygiene.#
ALCHEMPro News Desk (RKS)
marketing@alchempro.com
